COCHW · Envoy Medical, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Since inception, the Company has historically incurred negative operating cash flows and losses from operations as the Company advances the clinical development of its products and the funding process of clinical FDA trials. These matters raise substantial doubt about the Company's ability to continue as a going concern and although management has developed plans intended to support ongoing operations, such plans do not alleviate the substantial doubt.”View the 10-Q filed Aug 10, 2026
Price & Indicators
The closing range uses available history since Jul 23, 2026; less than a full year is stored.
Up next
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COCHW
this stock
Envoy Medical, Inc.
|
$46.00M | — | +7.1% | — | — |
|
ABT
Abbott Laboratories
|
$178.00B | -18.2% | +5.7% | 33.1 | 0.8% |
|
MDT
Medtronic plc
|
$119.00B | +0.6% | +8.4% | 22.9 | 3.1% |
|
SYK
Stryker Corp
|
$116.40B | -12.6% | +11.2% | 31.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.68B | -51.7% | +12.5% | 18.6 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 16, 2026
- This year
- 29
Envoy Medical, Inc. said its stockholders at the October 12, 2026 Special Meeting approved giving the Board discretion to effect reverse stock splits of Class A Common Stock at ratios from 1-for-5 to 1-for-25 through December 31, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COCHW | -29.0% | -2.6% | — | -3.8% | — |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -29.5% | -3.3% | — | -5.2% | — |